Insights Into Cisplatin-Induced Ototoxicity in Localized, Nonmetastatic Solid Tumors
Perspectives of community physicians from across the US on existing and emerging treatments for managing cisplatin-induced toxicities in localized, nonmetastatic solid tumors, including the current landscape, challenges, and future directions
Faculty Chair
Noah Federman, MD
UCLA David Geffen School of Medicine, Los Angeles, CA, USA
Faculty Chair
Ralph V. Boccia, MD, FACP
Georgetown University, Washington, DC, USA
Faculty Chair
Noah Federman, MD
UCLA David Geffen School of Medicine, Los Angeles, CA, USA
Faculty Chair
Ralph V. Boccia, MD, FACP
Georgetown University, Washington, DC, USA
Faculty Chair
Ralph V. Boccia, MD, FACP
Georgetown University, Washington, DC, USA
More Information
- Virtual
- Cancer Center of Kansas
More Information
- Virtual
- New York, New Jersey, Massachusetts, Delaware
More Information
- Virtual
- Illinois, Indiana, Pennsylvania, Ohio
More Information
- Virtual
- California, Nevada, Arizona, Washington
More Information
- Virtual
- Georgia, North Carolina, Tennessee, South Carolina
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on existing and emerging treatments for managing cisplatin-induced toxicities in localized, nonmetastatic solid tumors, including the current landscape, challenges, and future directions
- Disease state and data presentations were developed in conjunction with a national or regional oncology expert
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists representative of each region
